Liver cancer – HCC
Very early Hepatocellular carcinoma
The global incidence of liver cancer is increasing, growing 3% per year in Asia and Europe, and around 1-2% in the United States
Identifying HCC patients at very early stage (stage 0) is a huge clinical unmet need
Current imaging diagnostics offer poor sensitivity for small lesions (1-2cm)
Median’s eyonis® HCC
Unrivalled AI/ML Software as Medical Device (SaMD) enabling very early HCC diagnosis with unprecedented performance
The only end-to-end AI/ML tech-based CADe/CADx SaMD for very early stage HCC
Indicated for the detection, localization, and characterization of small nodules below 2cm
Unprecedented sensitivity and specificity versus standard of care
A radiological CADe device is “intended to identify, mark, highlight or otherwise direct attention to portions of an image that may reveal abnormalities during interpretation of images by the clinician”. A CADx device is “intended to provide information beyond identifying abnormalities, such as an assessment of disease”. Source: FDA
Additional indications
Lung cancer
Lung cancer screening (LCS) & incidental pulmonary nodules (IPN)
About eyonis®
Early diagnosis & treatment of cancer
Latest news
Webcast
eyonis® LCS successfully meets primary endpoint in RELIVE pivotal study: next steps towards marketing authorizations
KOL webinar
The eyonis® Lung Cancer Screening (LCS) REALITY data – What leading U.S. clinical pulmonology experts are saying
PRESS RELEASE
eyonis® Lung Cancer Screening (LCS) meets primary endpoint in RELIVE clinical trial, the final pivotal study required for regulatory submissions
